Von dem Buch Fast Facts: CAR T-Cell Therapy in Diffuse Large B-Cell Lymphoma haben wir 2 gleiche oder sehr ähnliche Ausgaben identifiziert!
Falls Sie nur an einem bestimmten Exempar interessiert sind, können Sie aus der folgenden Liste jenes wählen, an dem Sie interessiert sind:
100%: Buka, Richard J.;Moloney, Dee: Fast Facts: CAR T-Cell Therapy in Diffuse Large B-Cell Lymphoma (ISBN: 9783318070248) Karger / S. Karger, in Englisch, Taschenbuch.Nur diese Ausgabe anzeigen…
100%: R. J. Buka/ D. Moloney: Fast Facts: CAR T-Cell Therapy in Diffuse Large B-Cell Lymphoma (ISBN: 9783318069358) Fast Facts: CAR T-Cell Therapy in Diffuse Large B-Cell Lymphoma - eBook als epub von R. J. Buka/ D. Moloney - Karger - 9783318069358, in Englisch, auch als eBook.Nur diese Ausgabe anzeigen…
Fast Facts: CAR T-Cell Therapy in Diffuse Large B-Cell Lymphoma
3 Angebote vergleichen
Bester Preis: € 15,99 (vom 01.10.2021)1
Fast Facts: CAR T-Cell Therapy in Diffuse Large B-Cell Lymphoma
~EN NWISBN: 9783318070248 bzw. 3318070246, vermutlich in Englisch, Karger / S. Karger, neu.
Lieferung aus: Deutschland, Erscheint vorauss. 30. September 2021, Versandkostenfrei innerhalb von Deutschland.
Diffuse large B-cell lymphoma (DLBCL) is the most common form of high-grade non-Hodgkin lymphoma. While treatment with immunochemotherapy has generally shown good outcomes, specific subgroups of patients with high-risk disease have an unfavorable prognosis. Extensive efforts have been made to improve outcomes in these patients. As such, CD19-targeted chimeric antigen receptor (CAR) T-cell therapy has become the new standard of care for patients with relapsed or refractory DLBCL after at least two prior lines of therapy. It is an exciting new therapeutic intervention that is integral to the concept of personalized medicine. Table of Contents: -DLBCL: an overview -CAR T cells -CAR T-cell products -Delivering CAR T-cell therapy and managing patient expectations -CAR T-cell therapy-related toxicities.
Diffuse large B-cell lymphoma (DLBCL) is the most common form of high-grade non-Hodgkin lymphoma. While treatment with immunochemotherapy has generally shown good outcomes, specific subgroups of patients with high-risk disease have an unfavorable prognosis. Extensive efforts have been made to improve outcomes in these patients. As such, CD19-targeted chimeric antigen receptor (CAR) T-cell therapy has become the new standard of care for patients with relapsed or refractory DLBCL after at least two prior lines of therapy. It is an exciting new therapeutic intervention that is integral to the concept of personalized medicine. Table of Contents: -DLBCL: an overview -CAR T cells -CAR T-cell products -Delivering CAR T-cell therapy and managing patient expectations -CAR T-cell therapy-related toxicities.
2
Fast Facts: CAR T-Cell Therapy in Diffuse Large B-Cell Lymphoma
~EN PB NWISBN: 3318070246 bzw. 9783318070248, vermutlich in Englisch, Karger, Taschenbuch, neu.
Fast Facts: CAR T-Cell Therapy in Diffuse Large B-Cell Lymphoma ab 19.49 € als Taschenbuch: A practical resource for nurses. Aus dem Bereich: Bücher, Wissenschaft, Medizin,.
3
Fast Facts: CAR T-Cell Therapy in Diffuse Large B-Cell Lymphoma
~EN NW EB DLISBN: 9783318069358 bzw. 3318069353, vermutlich in Englisch, Fast Facts: CAR T-Cell Therapy in Diffuse Large B-Cell Lymphoma - eBook als epub von R. J. Buka/ D. Moloney - Karger - 9783318069358, neu, E-Book, elektronischer Download.
Fast Facts: CAR T-Cell Therapy in Diffuse Large B-Cell Lymphoma ab 1.18 € als epub eBook: A practical resource for nurses. Aus dem Bereich: eBooks, Fachthemen & Wissenschaft, Medizin,.
Lade…